Raymond Francot

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

The Founders Fund, Inc. provides financial assistance to students. It offers scholarships and sponsoring solutions to students for them to defray the cost of attending colleges, universities, and professional programs. The company was founded in 1991 and is headquartered in Naples, FL.

Myriad Genetics GmbH provides clinical diagnostic test services. It specializes in generic testing and disease diagnostic services. The company is headquartered in Zurich, Switzerland.